Hope Rugo, MD, on Clinical Implications of New Findings on the Benefits of Sacituzumab Govitecan-hziy in Advanced Breast Cancer

Posted: Monday, June 27, 2022

Hope Rugo, MD, of the University of California, San Francisco, discusses new data from the phase III TROPiCS-02 trial. Dr. Rugo also focuses on practical clinical issues such as whether the results of the trial represent a potentially practice-changing option for women with HER2-low breast cancer, which patients with breast cancer are ideal candidates for sacituzumab govitecan-hziy, and how to give and monitor this agent more safely and manage adverse events so patients can stay on therapy longer.